Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal mitoxantrone hydrochloride plus capecitabine versus capecitabine in platinum-failed recurrent/metastatic nasopharyngeal carcinoma
CTR20230112Phase 3Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitoxantrone hydrochloride liposome, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by CSPC Zhongnuo Pharmaceutical. Started Mar 2023; status: active.
02
Drugs
mitoxantrone hydrochloride liposomecapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20230112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230112.